Charles Schwab’s Bio-Techne TECH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$115M Sell
1,622,416
-14,146
-0.9% -$764K 0.02% 713
2026
Q1
$85.5M Buy
1,636,562
+77,418
+5% +$4.65M 0.01% 811
2025
Q4
$91.7M Sell
1,559,144
-20,496
-1% -$1.25M 0.01% 766
2025
Q3
$87.9M Buy
1,579,640
+27,200
+2% +$1.46M 0.01% 796
2025
Q2
$79.9M Buy
1,552,440
+41,180
+3% +$2.07M 0.01% 791
2025
Q1
$88.6M Buy
1,511,260
+45,570
+3% +$3.09M 0.02% 712
2024
Q4
$106M Buy
1,465,690
+51,687
+4% +$3.8M 0.02% 634
2024
Q3
$113M Sell
1,414,003
-88,911
-6% -$6.68M 0.02% 598
2024
Q2
$108M Buy
1,502,914
+34,467
+2% +$2.54M 0.02% 610
2024
Q1
$103M Buy
1,468,447
+28,528
+2% +$2.04M 0.02% 598
2023
Q4
$111M Buy
1,439,919
+28,095
+2% +$1.85M 0.03% 511
2023
Q3
$96.1M Sell
1,411,824
-5,340
-0.4% -$422K 0.03% 518
2023
Q2
$116M Buy
1,417,164
+8,527
+0.6% +$685K 0.03% 455
2023
Q1
$105M Buy
1,408,637
+9,970
+0.7% +$768K 0.03% 476
2022
Q4
$116M Buy
1,398,667
+45,083
+3% +$3.58M 0.04% 429
2022
Q3
$96.1M Buy
1,353,584
+33,232
+3% +$2.87M 0.03% 461
2022
Q2
$114M Buy
1,320,352
+45,888
+4% +$4.3M 0.04% 399
2022
Q1
$138M Buy
1,274,464
+43,060
+3% +$4.44M 0.04% 398
2021
Q4
$159M Buy
1,231,404
+40,544
+3% +$4.97M 0.05% 365
2021
Q3
$144M Buy
1,190,860
+296,536
+33% +$36.1M 0.05% 358
2021
Q2
$101M Buy
894,324
+20,192
+2% +$2.13M 0.03% 488
2021
Q1
$83.5M Sell
874,132
-54,152
-6% -$4.94M 0.03% 546
2020
Q4
$73.7M Buy
928,284
+15,820
+2% +$1.15M 0.03% 560
2020
Q3
$56.5M Buy
912,464
+10,048
+1% +$654K 0.03% 606
2020
Q2
$59.6M Sell
902,416
-81,848
-8% -$4.9M 0.03% 549
2020
Q1
$46.7M Buy
984,264
+10,060
+1% +$503K 0.03% 553
2019
Q4
$53.5M Buy
974,204
+46,868
+5% +$2.46M 0.03% 581
2019
Q3
$45.4M Buy
927,336
+62,284
+7% +$3.12M 0.03% 643
2019
Q2
$45.1M Buy
865,052
+25,076
+3% +$1.26M 0.03% 620
2019
Q1
$41.7M Buy
839,976
+20,272
+2% +$912K 0.03% 640
2018
Q4
$29.7M Buy
819,704
+3,540
+0.4% +$148K 0.02% 726
2018
Q3
$41.6M Sell
816,164
-278,668
-25% -$12.3M 0.03% 625
2018
Q2
$40.5M Buy
1,094,832
+105,220
+11% +$4.02M 0.03% 605
2018
Q1
$37.4M Buy
989,612
+163,572
+20% +$5.78M 0.03% 616
2017
Q4
$26.8M Buy
826,040
+37,304
+5% +$1.19M 0.02% 775
2017
Q3
$23.8M Buy
788,736
+52,296
+7% +$1.55M 0.02% 796
2017
Q2
$21.6M Buy
736,440
+21,788
+3% +$596K 0.02% 802
2017
Q1
$18.2M Buy
714,652
+56,476
+9% +$1.46M 0.02% 891
2016
Q4
$16.9M Buy
658,176
+44,068
+7% +$1.16M 0.02% 868
2016
Q3
$16.8M Buy
614,108
+47,756
+8% +$1.31M 0.02% 800
2016
Q2
$16M Buy
566,352
+21,712
+4% +$558K 0.02% 772
2016
Q1
$12.9M Buy
544,640
+23,312
+4% +$513K 0.02% 880
2015
Q4
$11.7M Buy
521,328
+24,088
+5% +$549K 0.02% 911
2015
Q3
$11.5M Buy
497,240
+36,692
+8% +$920K 0.02% 900
2015
Q2
$11.3M Buy
460,548
+38,628
+9% +$965K 0.02% 936
2015
Q1
$10.6M Buy
421,920
+52,244
+14% +$1.24M 0.01% 964
2014
Q4
$8.54M Buy
369,676
+28,448
+8% +$651K 0.01% 1007
2014
Q3
$7.98M Buy
341,228
+16,856
+5% +$395K 0.01% 996
2014
Q2
$7.51M Buy
324,372
+9,644
+3% +$213K 0.01% 1063
2014
Q1
$6.72M Buy
314,728
+22,068
+8% +$497K 0.01% 1092
2013
Q4
$6.93M Buy
292,660
+25,196
+9% +$546K 0.01% 1002
2013
Q3
$5.47M Buy
267,464
+19,544
+8% +$371K 0.01% 1101
2013
Q2
$4.32M Buy
+247,920
New +$4.12M 0.01% 1188

Other funds holding TECH

Charles Schwab's TECH Position: Q2 2026 in Review

Charles Schwab reduced its Bio-Techne (TECH) stake by 0.86% in Q2 2026, selling an estimated $764K and leaving 1,622,416 shares worth $115M. The position accounts for 0.02% of the portfolio, ranked #713.

Charles Schwab first reported a position in TECH in Q2 2013 and has held it in 53 quarters since. The position peaked at $159M in Q4 2021. 593 funds tracked by Wall St. Rank hold TECH as of Q2 2026.

  • Charles Schwab held 1,622,416 shares of Bio-Techne worth $115M as of Q2 2026.
  • Charles Schwab sold 14,146 Bio-Techne shares in Q2 2026, an estimated $764K.
  • Bio-Techne made up 0.02% of Charles Schwab's portfolio in Q2 2026, its #713 holding.
  • Charles Schwab first reported a position in Bio-Techne in Q2 2013 and has held it in 53 quarters since.
  • Charles Schwab's Bio-Techne position peaked at $159M in Q4 2021.
  • 593 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.